FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH . . . In June 2017, the FDA approved a refined indication for Vectibix for use in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC, specifically as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with
FDA Approval Summary: Fruquintinib for the Treatment of . . . On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, −2, and −3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with
U. S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as . . . This release contains forward-looking information about the BRAFTOVI® (encorafenib) plus cetuximab and mFOLFOX6 combination and a new indication in the U S for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, including their potential benefits and discussions
The FDA Approves Sotorasib With Panitumumab for Treatment of . . . CRC is the third leading cause of cancer-related mortality in the United States, accounting for approximately 11% of all diagnoses Although survival outcomes in earlier stages of disease are favorable, those with metastatic disease or mutations have significantly worse outcomes KRAS G12C mutations occurs in an estimated 3% to 4% of patients with mCRC and are among the most common genetic
FDA Oks Sotorasib Panitumumab in KRAS G12C-Mutant Colorectal . . . The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated metastatic colorectal cancer (CRC) The approval